# Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

> **NCT02203903** · PHASE1 · RECRUITING · sponsor: **Catherine Bollard** · enrollment: 50 (estimated)

## Conditions studied

- Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS

## Interventions

- **BIOLOGICAL:** Tumor associated antigen lymphocytes (TAA-T)

## Key facts

- **NCT ID:** NCT02203903
- **Lead sponsor:** Catherine Bollard
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2015-01-01
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-06-28
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-05-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02203903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02203903, "Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02203903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*